Accent Microcell ACCENTMIC

Summary

Accent Microcell is the cleanest listed expression of the excipient thesis set out in this primer: a focused, export-led microcrystalline cellulose producer with a US Drug Master File, an essentially debt-free balance sheet and a five-year record of compounding revenue in the high teens without dilution or leverage. FY26 was its strongest year — total income up 31% to Rs 355.8 crore and profit after tax up 33% to Rs 43.9 crore — and CARE upgraded it to A–/Stable in March 2026.

Our reservation is entirely about timing. The company is capacity-constrained: it sold roughly 15,000 tonnes in FY26 against 9,200 MTPA of installed capacity, buying in about 30% of volume at a distribution spread rather than a conversion margin. The answer to that is Unit-III at Nayka, Kheda — and Unit-III has slipped from October 2025 to April 2026 and then again, with no revised date, on monsoon disruption and pending environmental and power-line approvals. Meanwhile the stock has risen from a 52-week low of Rs 238 to Rs 697.

At roughly 37x FY26 earnings and about 6x book, the shares already discount a plant that has not yet made a kilogram. Our SOTP-free, earnings-based target price of Rs 730 — 28x FY28E EPS of Rs 25.5 — implies 5% upside. We initiate with a HOLD.

Why the business deserves a premium at all

Excipient revenue is unusually sticky. An excipient has no standalone approval; it is qualified inside the customer's drug filing, so replacing a supplier means a monograph check, a DMF reference, an audit, formulation trials, stability data and a regulatory variation — three to five years in total. Accent's DMF, FSSC 22000/GMP/HACCP certifications and Kosher and Halal approvals are what convert a commodity powder into that kind of relationship. Roughly half of income is export, and the top ten customers were about 44% of income in FY25 — concentrated, but concentrated in relationships that are slow to lose.

• A pure-play on the one tile of the value chain that converts commodity into specification. Accent buys wood pulp — a globally traded commodity — and sells a particle specification backed by a dossier. Section 3 of this primer showed why that conversion is where margin sits: in a commodity powder the pulp is roughly two-thirds of cost; in a specified pharmaceutical grade, process, analytics and documentation dominate. Accent has held a 16–18% EBITDA margin through a pulp cycle, which is the evidence that the conversion is real.
• The mix upgrade is the whole equity story, and it is credible. Unit-III Phase 1 adds roughly 2,400 MTPA of croscarmellose sodium, sodium starch glycolate and CMC — functional derivatives that sit one full rung above standard MCC on the grade ladder, with croscarmellose reportedly around 70% of the intended mix. Phase 2 adds about 12,000 MTPA of MCC, moving total capacity toward 24,000 MTPA against 9,200 today, for a combined outlay of roughly Rs 105–110 crore funded from IPO and rights-issue proceeds rather than debt.
• Two mechanical margin levers, independent of pricing. First, the traded share of volume — about 30% in FY26 — earns a distribution spread. As own capacity commissions, that share should fall and blended margin should rise without any pricing increase. Second, derivatives carry structurally better realisation than standard MCC. Our FY28E margin of 17.5% assumes both work only partially.
• Balance sheet that can absorb a delay. Gearing of 0.01x, interest cover above sixty times, working-capital limit utilisation around a tenth, and a net worth that crossed Rs 250 crore after the June 2025 rights issue. A stretched project timetable is an opportunity cost here, not a solvency question — which is precisely why our concern is valuation rather than risk of ruin.
• Captive power reduces a real cost line. The 4.45 MW wind turbine ordered from Inox Wind in August 2026 addresses electricity, which is a meaningful input in a hydrolysis-and-spray-drying process. It also signals that Unit-III is being provisioned for as a live project.

Source: Company filings; CARE Ratings; Dart Consultants estimates for FY27E–FY28E.

Source: Company disclosures. FY26 volume of ~15,000 MT comprised approximately 70% manufactured and 30% traded. Capacity additions are as announced; Phase 2 timing is not confirmed.

• Unit-III has slipped twice and has no revised date. Commercial production was indicated for October 2025, then April 2026. The company then notified the exchange of further delay, citing two abnormal monsoon seasons and difficulties obtaining environmental clearance and power transmission approval. Our FY27E and FY28E numbers assume a partial Phase 1 contribution and a late, partial Phase 2. If both land as originally planned, we are too conservative; if they slip another year, our FY28E is roughly 15% too high.
• Industry capacity is arriving all at once. Accent's roughly 14,400 MTPA of additions and Sigachi's announced 12,000 MT land in the same window, into a global MCC market growing at 6–7%. Both Indian producers are making the same bet simultaneously, and it argues for watching realisation per tonne rather than tonnage.
• Input and currency exposure without a hedging policy. Wood pulp is the principal raw material and is partly imported, while output is largely exported. CARE notes the absence of an active hedging policy. A rupee move or a pulp spike therefore passes through to margin with a lag.
• Customer concentration. The top ten customers were about 44% of income in FY25, up from 39% in FY24. High switching costs cut both ways: the relationships are durable, but losing one is material and slow to replace.
• Liquidity and disclosure are SME-grade. Reporting is half-yearly, institutional coverage is negligible, and the promoter stake fell 2.45 percentage points in the most recent quarter. None of this changes the business; all of it widens the range of outcomes and argues for a higher required return.

Developments that would move our view

• Unit-III Phase 1 commercial production and, critically, disclosure of derivative revenue as a separate line. Phase 1 adds roughly 2,400 MTPA of croscarmellose sodium, sodium starch glycolate and CMC. The project has slipped from October 2025 to April 2026 and again, with no revised date given.
• Phase 2 timing — approximately 12,000 MTPA of MCC, taking capacity toward 24,000 MTPA.
• The traded-versus-manufactured mix. A fall in traded share from around 30% toward 20% should lift blended margin mechanically, with no price increase required.
• Realisation per tonne. The cleanest single indicator of whether grade mix is genuinely improving rather than volume simply growing.
• Commissioning of the 4.45 MW captive wind turbine ordered from Inox Wind in August 2026.
• H1 FY27 results, expected around November 2026 — the next hard data point under half-yearly reporting.
• Any main-board migration announcement, new DMF filings, or disclosure of a major customer qualification.

Key risks to be aware of

• Execution risk — the primary one. The investment case rests on a plant that has not yet produced. A further year of delay would put our FY28 estimate roughly 15% too high.
• Supply risk. Two Indian producers are roughly doubling capacity simultaneously into a market growing at 6–7%. If the new tonnage lands in standard rather than premium grades, pricing compresses.
• Input and currency risk. Wood pulp is partly imported and output largely exported, with no active hedging policy. Margin absorbs both moves with a lag.
• Concentration risk. The top ten customers are about 44% of income. High switching costs make those relationships durable but make any loss slow to replace.
• Quality and regulatory risk. A failed customer audit, a DMF deficiency or an impurity finding would cost qualified customers who, once re-qualified elsewhere, are protected by the same switching cost that currently protects Accent.
• Governance concentration risk. Combined MD and CFO roles, a family-majority board and half-yearly reporting widen the range of outcomes.
• Valuation and liquidity risk. At roughly 37x FY26 earnings after a near-tripling from the 52-week low, and on an SME platform with limited depth, the stock offers little cushion if any of the above materialises.

FY26 PAT of Rs 43.9 crore on 24.0 million shares gives FY26 EPS of Rs 18.65. Applying a constructed FY27E and FY28E EPS of Rs 20.6 and Rs 25.5 (partial Unit-III contribution, falling traded share), we apply a target multiple band around the current trailing multiple to reflect execution risk at the plant rather than assuming further re-rating:

Source: Dart Consultants estimates. The base multiple of 28x reflects a debt-free business compounding earnings in the high teens, discounted for SME listing, half-yearly reporting and an unproven project timetable. The company is essentially debt-free, so enterprise value approximates market capitalisation.

Source: Company filings and CARE Ratings publications for FY23–FY26; Dart Consultants estimates for FY27E–FY28E. FY26 EBITDA is derived from disclosed half-yearly operating profit. EPS reflects the share count in each year, which rose through the December 2023 IPO and the June 2025 rights issue.

Source: CARE Ratings press release dated 25 March 2026; company filings. We have deliberately restricted this table to disclosed or directly derivable metrics rather than modelling a full balance sheet, because the company reports half-yearly and several line items are not separately disclosed. Items marked "~" are derived. Dashes indicate not disclosed. Export share above 53% of revenue has also been separately indicated by the company.